Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 plus venetoclax in AML
2024-516294-78-00Phase 2Authorised
- Sponsor
- Taiho Oncology
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of inqovi and venetoclax in acute myeloid leukemia (AML), sponsored by Taiho Oncology. Primary endpoints: Phase 1 venetoclax AUC0-24 and Cmax on Day 5 with ASTX727 and Day 15 without ASTX727 in Cycle 2, Phase 2 Part A and B complete remission (CR) rate and 1 more. Planned start Aug 2024; status: authorised.
02
Drugs
inqovivenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-516294-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516294-78-00.